Sun Pharma shares in focus as management reiterates FY27 guidance; Analysts see up to 31% upside

What happened

Sun Pharma management reiterated high single-digit guidance for FY27 after its second-quarter results. It reported net profit down 32% to ₹1,988.5 crore, while revenue rose 11.9% to ₹16,198.7 crore. Management said Illumya sales slowed, but plans a November soft launch for its psoriatic arthritis use.

Confirmed

Global impact / market context

The profit decline despite higher revenue points to pressure on how much Sun Pharma keeps from sales. Illumya’s slowdown could limit growth, while the planned new-use launch may help revive it; the deal’s expected closure could also change the business, but timing and benefits remain uncertain.

Analyst inference

The article pairs management’s repeated growth guidance with weaker quarterly profit and slower Illumya sales, creating competing signals for investors. Revenue and earnings before interest, taxes, depreciation and amortization, a measure of operating profit, exceeded estimates, but the excerpt does not give the full cost breakdown.

Analyst inference

What to watch

1. Check whether Sun Pharma reports improved Illumya sales after identifying causes of the slowdown; stronger sales would support the company’s stated effort to revive growth. Analyst inference
2. Watch for completion of the Organon acquisition by the fourth quarter of this fiscal year, as management said approvals were secured in most markets and the deal remained on track. Confirmed
3. Compare future results with the reiterated FY27 high single-digit guidance, especially revenue and profit, to see whether growth translates into stronger earnings. Analyst inference

Evidence

• Original source link unavailable